MARTINSRIED / MUNICH, Germany, March 30, 2015 (GLOBE NEWSWIRE) -- MorphoSys AG Martinsried/Planegg Securities Code Number: 663200 ISIN: DE0006632003
Convenience Translation: The text decisive for the invitation to the Annual General Meeting of MorphoSys AG is the one written in the German language.
Invitation to the Annual General Meeting 2015 of MorphoSys AG
We hereby invite the shareholders of our Company to the Annual General Meeting taking place on Friday, 8 May 2015 at 10:00 a.m., at the Conference Center Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636 Munich.
Agenda
- Presentation of the adopted financial statements and the approved consolidated financial statements as of 31 December 2014; the management reports, including the report of the Supervisory Board for the 2014 financial year; and the explanatory report of the Management Board regarding the disclosures pursuant to sections 289 para. (4) and 315 para. (4) German Commercial Code (HGB)
- Resolution on the appropriation of the accumulated income of MorphoSys AG for the 2014 financial year
- Resolution on the discharge of the members of the Management Board with respect to the 2014 financial year
- Resolution on the discharge of the members of the Supervisory Board with respect to the 2014 financial year
- Resolution on the appointment of the auditor for the 2015 financial year
- Resolution on the cancelation of Authorized Capital 2013-I and the creation of new Authorized Capital 2015-I with the option to exclude the pre-emptive rights of shareholders; amendments to the Articles of Association
- Resolution on the election of Supervisory Board members
- Resolution on the adjustment in remuneration of the Supervisory Board
- Resolution on the amendments to the Articles of Association
Please find the full text of the invitation here: www.morphosys.com/agm
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 90 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.
Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com
HUG#1907421